Endometrial Cancer Market Size, Share & Trends Analysis Report By Type Of Cancer (Endometrial Carcinoma, Uterine Sarcomas), By Type Of Therapy, By Diagnosis Method, By Region, And Segment Forecasts, 2023 - 2030

Endometrial Cancer Market Size & Trends

The global endometrial cancer market size was valued at USD 25.10 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.69% from 2023 to 2030. This is attributed to the rising incidence of endometrial cancer, growing advancements in early detection & diagnosis, and increasing number of research & development in the oncology fields. Moreover, the increasing adoption of personalized medicines & targeted therapies is anticipated to further fuel the growth of the market from 2023 to 2030.

According to the Australia New Zealand Gynaecological Oncology Group, each year, over 3,000 Australians and 700 New Zealanders receive a diagnosis of uterine cancer. In Australia, this indicates a doubling of case numbers over the past two decades, and globally, the trend of rising endometrial cancer diagnoses is expected to continue, with estimates signifying a further increase of over 50% by 2040. 

Furthermore, the growing awareness programs and partnerships related to endometrial cancer are anticipated to impel the market growth. In March 2021, Eisai Inc. initiated a campaign named 'Spot Her' designed to break the silence about endometrial cancer and encourage women to actively engage, promote awareness, and prioritize both their own health and that of fellow women. This campaign was carried out in collaboration with Black Health Matters, Facing Our Risk of Cancer Empowered (FORCE), and SHARE Cancer Support (SHARE).

Type Of Cancer Insights

Endometrial carcinoma held the largest market share in 2022 and is anticipated to grow at the fastest CAGR over the forecast period. This is due to the rising incidence of endometrial cancer globally, particularly in developed countries, due to various factors such as obesity, diabetes, and hormone replacement therapy, as well as a trend towards delayed childbearing. Endometrial carcinoma is further segmented into adenocarcinoma, carcinosarcoma, squamous cell carcinoma, and other types of cancer.

Type Of Therapy Insights

On the basis of type of therapy, the market is segmented into immunotherapy, radiation therapy, chemotherapy, and other types of therapies. The chemotherapy segment dominated the market in 2022 due to the efficacy of chemotherapy in treating both early and advanced stages of endometrial cancer, offering a systemic approach to eradicate cancer cells that could spread beyond the uterus. On the other hand, immunotherapy is anticipated to grow at the fastest CAGR from 2023 to 2030.

Diagnosis Method Insights

Based on the diagnosis method, the endometrial cancer market is segmented into biopsy, CT scan hysteroscopy, pelvic ultrasound,and other diagnosis methods. The biopsy segment dominated the market in 2022. The advancements in imaging techniques and biopsy procedures, including guided imaging technologies, have enhanced the precision and effectiveness of endometrial biopsies. Thus, the adoption of advanced technology for effective treatment is anticipated to boost the segment growth.

The pelvic ultrasound is projected to grow at the fastest CAGR over the forecast period. This is attributed to its non-invasive nature, cost-effectiveness, and ability to provide real-time imaging of the uterus and surrounding structures.

Regional Insights

North America dominated the market in 2022. This is attributed to the rising awareness among citizens regarding cancer diagnosis as well as the well-established healthcare infrastructure. According to the June 2023 publication by the American Cancer Society, in 2020, approximately 65,950 new instances of uterine body or corpus cancer were projected to be identified in the U.S. Endometrial cancer primarily affects females who have undergone menopause, with the typical age of diagnosis being around 60 years old. Furthermore, in April 2022, a clinical research study, supported by Sunnybrook Health Sciences Centre in Canada, was conducted to evaluate the impact of megestrol acetate on patients with grade 2 endometrioid endometrial cancer who were in the preoperative phase, awaiting definitive surgery. Thus, the growing number of clinical studies is further anticipated to propel the growth of the market in the region. Asia Pacific, on the other hand, is projected to grow at the fastest CAGR over the forecast period.

Key Companies & Market Share Insights

Key players operating in the market are Bristol-Myers Squibb Company, Siemens Healthineers (Varian Medical Systems, Inc.), Elekta AB, R-Pharm-US LLC, and Pfizer Inc., among others. The market participants are constantly working towards new product development, R&D activities, and other strategic alliances to gain new market avenues.

The following are some instances of strategic initiatives:

• In October 2022, a Japan-based organization, Sysmex Corporation, announced the consent of a partial modification to the developing and marketing authorization in Japan for its gene amplificating component, LYNOAMP CK19. Originally promoted as a lymph node metastasis exam component for gastric cancer, colorectal cancer, non-small cell lung cancer, and breast cancer. The modification prolongs the amplification capabilities to include endometrial cancer and cervical cancer.

• In February 2022, Karyopharm Therapeutics Inc., a U.S.-based organization, announced positive preliminary outcomes from the Phase 3 investigation of Selinexor for endometrial cancer. This study evaluated the safety and effectiveness of selinexor as a first-line maintenance therapy in patients dealing with advanced or recurrent endometrial cancer.